# Evaluation of NWRD09 for HPV-16 Related Cervical HSIL

> **NCT07712692** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Newish Biotech (Wuxi) Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- High-grade Squamous Intraepithelial Lesion (HSIL)

## Interventions

- **BIOLOGICAL:** NWRD09 Injection
- **BIOLOGICAL:** NWRD09 Placebo

## Key facts

- **NCT ID:** NCT07712692
- **Lead sponsor:** Newish Biotech (Wuxi) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712692, "Evaluation of NWRD09 for HPV-16 Related Cervical HSIL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*